db987 against full length recombinant human pde9 (Sino Biological)
Structured Review

Db987 Against Full Length Recombinant Human Pde9, supplied by Sino Biological, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/h07e/pm37726213-162-6-13?v=Sino+Biological
Average 91 stars, based on 1 article reviews
Images
1) Product Images from "Virtual Screening-Accelerated Discovery of a Phosphodiesterase 9 Inhibitor with Neuroprotective Effects in the Kainate Toxicity In Vitro Model."
Article Title: Virtual Screening-Accelerated Discovery of a Phosphodiesterase 9 Inhibitor with Neuroprotective Effects in the Kainate Toxicity In Vitro Model.
Journal: ACS chemical neuroscience
doi: 10.1021/acschemneuro.3c00431
Figure Legend Snippet: Figure 1. Chemical structure of the chromone scaffold used for the virtual screening procedure (A). Chemical structure of DB987, the compound highlighted by the screening, in which the red structure represents the part of the molecule matching query (B). Chemical structure of the reference compound, PDE9 inhibitor PF-04447943 (C).
Techniques Used:
Figure Legend Snippet: Figure 2. Binding poses for PF-04447943 (A) and DB987 (B) in the predicted interaction pattern with PDE9. The residues at the interaction distance (<5 Å) within the binding pocket have been labeled.
Techniques Used: Binding Assay, Labeling
Figure Legend Snippet: Figure 5. (A-B2) Immunohistochemical assessment of neuronal damage and PDE9 expression in the CA3 hippocampus of organotypic slices after treatment with KA. (A1,B1) Representative confocal images of fluorescent immunostaining of NeuN-positive neurons in area CA3 of CRL (A1) and KA (B1) slices. (A2,B2) Representative confocal images of fluorescent immunostaining of PDE9 in area CA3 of CRL (A2) and KA-treated slices (B2). (A, B) Merge of the previous images. All images were captured with a 20× objective. Scale bar: 100 μm. (C-C2) Magnifications of the framed areas of the corresponding slice shown in B, B1, and B2. (C1) Immunostaining of NeuN showing the presence of damaged neurons with an elongated, shrunk cytoplasm. (C2) Immunostaining of PDE9 showing the expression of the enzyme in many CA3 pyramidal neurons (open arrows). (C) Merge of the two previous images (open arrows indicate neurons positive for PDE9 immunostaining). Scale bar: 25 μm. (D) Quantitative analysis of PDE9 immunostaining in CA3 SP (CRL n = 10 and KA n = 9). Statistical analysis: Student’s t-test: **P < 0.01 KA vs CRL. (E-F3) Representative confocal images of triple immunofluorescent labeling of neurons (NeuN, red), PDE9 (green), and astrocytes (GFAP, blue) in CA3 of KA-treated slices captured with a 40× objective. Open arrows indicate PDE9-positive pyramidal neurons. No colocalization with astrocytes was found. Scale bars: 70 μm (E) and 15 μm (F-F3).
Techniques Used: Immunohistochemical staining, Expressing, Immunostaining, Labeling
Figure Legend Snippet: Figure 7. Qualitative and quantitative analyses of the effects of PDE9 inhibitors in rat organotypic hippocampal slices under normal conditions or exposed to KA. (A) Hippocampal slice under normal conditions (background PI fluorescence), (B) slice exposed to 10 μM PF for 24 h, (C) slice exposed to 10 μM DB987 for 24 h, (D) slice exposed to 5 μM KA for 24 h displaying intense PI labeling in the CA3 subregion, and (E,F) CA3 damage induced by KA was attenuated by the presence of 1 μM PF and DB987. (G) PDE9 inhibitors alone did not induce side effects. (H) PDE9 inhibitors significantly attenuated CA3 damage in a dose-dependent manner. Bars represent the mean ± SEM of at least five experiments run in quadruplicate. **p < 0.01 and ***p < 0.001 vs KA (one-way ANOVA plus Dunnett’s test).
Techniques Used: Fluorescence, Labeling



